GlassScriptPhysician profile
Christopher James Berg
NPI 1598296147
$2,578.43
in general payments reported to CMS, 2019-2025
28 companies · $964 in 2025
The $964 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.70 · 2022: $130 · 2023: $461 · 2024: $1,005 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.67 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $393.14 | 2023-2025 | |
| Atricure, INC. | $263.18 | 2023-2025 | Atriclip Laa Exclusion System |
| Alnylam Pharmaceuticals INC. | $238.47 | 2023-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $158.05 | 2023-2025 | Farxiga, Wainua |
| Biotronik INC. | $148.44 | 2021-2022 | |
| Amgen INC. | $109.43 | 2023-2025 | Repatha |
| Pfizer INC. | $92.92 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $82.26 | 2024 | Arcalyst |
| Boston Scientific Corporation | $71.95 | 2025 | Wavewriter Alpha Prime 16 |
| Regeneron Healthcare Solutions, INC. | $61.24 | 2023-2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $52.76 | 2023-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.68 | 2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $40.48 | 2023-2024 | |
| Scpharmaceuticals INC. | $39.75 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $39.07 | 2025 | |
| Esperion Therapeutics, INC. | $38.79 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $34.33 | 2024-2025 | Verquvo |
| Medtronic, INC. | $34.15 | 2024 | Onyx Frontier |
| Bridgebio Pharma, INC. | $31.50 | 2025 | Attruby |
| Ionis Pharmaceuticals, INC. | $30.50 | 2025 | Tryngolza |
| Bayer Healthcare Pharmaceuticals INC. | $30.14 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $21.04 | 2023 | Arcalyst |
| Altathera Pharmaceuticals LLC | $20.68 | 2025 | Sotalol Hydrochloride |
| Lilly USA, LLC | $19.39 | 2024 | Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $19.13 | 2023 | Xarelto |
| Novo Nordisk INC | $19.09 | 2024 | Ozempic |
| Zoll Respicardia, INC. | $14.20 | 2025 | Remede System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.